ClinicalTrials.gg
TerminatedNCT01552590ECFUpdated Mar 4, 2022

Effect of Samsca on Control of Hyponatremia and Extracellular Fluid in Cirrhotic Patients With Ascites

A Phase 4 interventional study of Tolvaptan and Placebo in Hyponatremia and Extracellular Fluid in Cirrhotic, sponsored by Korea Otsuka Pharmaceutical Co., Ltd.. Terminated at 3 sites in Korea, Republic of. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2022-03-04.

Sponsored by Korea Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
74
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing tolvaptan in Hyponatremia — none open to participants now, none under way, none of them phase 3. Tolvaptan · Hyponatremia.

Enrollment
8th of 20
74 · median 55
Started
2012
with 4 others
Phase 4
7 of 20
none open now
Registered
9th of 20
by date
Lead sponsor
2 of 20
Korea Otsuka Pharmaceutical Co., Ltd.

Among the 20 studies testing tolvaptan in Hyponatremia, this one is the 8th largest by enrollment, is one of 5 that started in 2012, is one of 7 in phase 4, and was the 9th registered.

Hyponatremia

164 studies on the registry are indexed under Hyponatremia; 16 are open to participants now.

Browse Hyponatremia studies →

Open to participants now

None of the 20 studies testing tolvaptan in Hyponatremia is open now. The open studies under Hyponatremia, anywhere →

About tolvaptan

Tolvaptan: first FDA approval 2009 (SAMSCA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 14 Hyponatremia studies recruiting now, 13 (93%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 20 studies testing tolvaptan in Hyponatremia as a file.
02

Study summary

This study is to evaluate the efficacy of a 2-week course of tolvaptan in improving serum sodium and the excretion of extracellular fluid in liver cirrhotic patients with ascites and hyponatremia

03

Conditions studied

  • Hyponatremia and Extracellular Fluid in Cirrhotic

Browse trials for

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects aged ≥ 20 years
  2. Subjects who have been diagnosed with hyponatremia [serum sodium \< 125 mEq/L or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction]
  3. Subjects who have been diagnosed with an ascites on the abdominal ultrasound.
  4. Subjects who have diagnosed with cirrhosis.
  5. Subject or their legally acceptable representatives are able to provide /assent.

Exclusion criteria

Exclusion Criteria:

  1. Subject who has ascites by other causes (Tbc, CHF, , or renal disease) acute severe hyponatemia : Serum Na level \< 120 mmol/L and Doubt of symptom caused by hyponatremia and the case which should raise serum Na level urgently based on the investigator's judgment (INR) >3.0 serum sodium ≥135 mmol/L serum potassium > 5.5 mmol/L Creatinine ≥ 2.0 mg/dL Hepatorenal syndrome defined as 'New International Ascites Club's diagnostic criteria' systolic arterial pressure of \< 80 mmHg recent myocardial infarction (\< 6 month) spontaneous bacterial peritonitis gastrointestinal bleed ( ≤7 days from randomization) ongoing hepatic encephalopathy of > grade1 known hepatocellular carcinoma intractable ascites
  2. Subject who requiring urgent intervention to raise serum sodium acutely
  3. Subject who are unable to sense or to respond appropriately to thirst
  4. Subject with hypovolemic hyponatremia
  5. Subject who should take strong inhibitors (clarithromycin, ketoconazole, itraconazole, ritonavir, indinavir, nelfinavir, saquinavir, nefazodone, and telithromycin)
  6. Subject who are anuric as no benefit is expected
  7. Subject who has genetic defects such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
  8. Subject who has fluid depletion
  9. Female subjects who are pregnant or lactating
  10. Subject judged by the investigator to be inappropriate for inclusion in the trial for any other reason
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
74 participants (actual)

Study arms

  • Active comparator
    Tolvaptan

    Tablet, QD, 2 weeks

    Drug: Tolvaptan

  • Placebo comparator
    Placebo

    Tablet, QD, 2 weeks

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Serum Na

    Time frame: 2 weeks (Baseline, Day 14)

Secondary outcomes

  1. BCM (body composition monitoring)

    Time frame: 7 days

  2. body weight

    Time frame: 7 days

  3. A composite endpoint of ascites worsening

    Time frame: in case

  4. Serum Na normalization rate

    Time frame: 14 days

  5. Biochemistry

    Total protein, Albumin, ALP, ALT, AST, r-GT, BUN, Creatinine, Glucose, Cl, K, Na, Ca, Total bilirubin, Uric acid), Hematology (WBC count, Hemoglobin, Hematocrit, Platelets, Serum osm, NT pro-BNP

    Time frame: 7 days

  6. ECG

    Time frame: 7 days

  7. Adverse event

    Time frame: Daily

  8. Physical examination

    HEENT, Thorax, Abdomen, Urogenital, Extremities, Neurological, Skin and Mucosae

    Time frame: 7 days

  9. Vital signs

    Time frame: Daily

  10. Blood coagulation

    PT, INR

    Time frame: 7 days

  11. Urinalysis

    Protein, pH, Glucose, Blood, Bilirubin, Urobilinogen, Random urine Na/K, Urine osm

    Time frame: 7 days

07

Study locations

3 sites
  • Hallym Univ. Chuncheon Sacred Heart Hospital
    Bucheon, Korea, Republic of
  • Soonchunhyang Univ. Bucheon Hospital
    Bucheon, Korea, Republic of
  • Wonju Christian Hospital
    Wonju, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2012, a primary completion of Apr 2012 and a completion of Apr 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2012
First posted
Mar 13, 2012
Start
Apr 2012
Primary completionActual
Apr 2012
CompletionActual
Apr 2012
Last update
Mar 4, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01552590
Responsible party
Sponsor
First posted
Mar 13, 2012
Start date
Apr 2012
Primary completion
Apr 2012
Completion
Apr 2012
Last update
Mar 4, 2022

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tolvaptan

Start the discussion